Anatara Lifesciences (ASX:ANR) has appointed a new CEO and has reported a fivefold increase in its net loss for the half-year ending in December due to spending on commercialisation efforts for lead product Detach. The company has named Dr Paul Schober to the CEO role, effective from next week. Schober is joining Anatara from animal health company Virbac, where he was general manager for the company’s Peptech division.
Help employers find you! Check out all the jobs and post your resume.
